Table 3.
Clinically important change on assessments of motor ability, function, HRQOL, and symptom severity between baseline and 6 months
| Measures | MCIDs |
|||
|---|---|---|---|---|
| Na | Value | Improve, n (%) | Decline, n (%) | |
| Motor | ||||
| JTHFT | 13 | 15.32b | 1 (7.1) | 1 (7.1) |
| GPT | 13 | 13.82b | 2(15.4) | 4 (30.8) |
| Grip strength (lbs) | 12 | 13.95b | 1 (8.3) | 1 (8.3) |
| Pinch strength (lbs) | ||||
| Tip-to-tip | 13 | 2.60b | 1 (7.7) | 0 (0.0) |
| Palmar | 13 | 2.84b | 4 (30.8) | 1 (7.7) |
| Key | 13 | 2.50b | 3 (23.1) | 1 (7.7) |
| 2MWT (ft) | 11 | 50.35b | 1 (9.1) | 1 (9.1) |
| Functional | ||||
| AMPS | ||||
| ADL Motor skill | 13 | 0.3 logitsc | 2(15.4) | 3 (23.1) |
| ADL Process skill | 13 | 0.3 logitsc | 3 (23.1) | 3 (23.1) |
| DASH | 12 | 15c | 3 (25.0) | 3 (25.0) |
| HAP | ||||
| AAS | 12 | 8.81b | 3 (25.0) | 1 (8.3) |
| MAS | 12 | 5.03b | 3 (25.0) | 1 (8.3) |
| MAM-36 | 12 | 7.60b | 5 (41.7) | 2 (16.7) |
| Quality of life | ||||
| SF-36 | ||||
| PCS | 12 | 5c | 3 (25.0) | 2 (16.7) |
| MCS | 12 | 5c | 4 (33.3) | 2 (16.7) |
| Symptom severity | ||||
| Provider Global Rating | 13 | 2c | 2(15.4) | 2 (15.4) |
| Lee Symptom Scale | 13 | 6.50c | 5 (38.5) | 2 (15.4) |
JTHFT, GPT, and pinch strength scores refer to performance with the dominant hand. Higher scores on the DASH, JTHFT, and GPT indicate poorer performance. Higher scores on the PGR and Lee Symptom Scale indicate greater symptom severity. On all other measures, higher scores indicate improved performance
Number ofpatients with data on each measure at both baseline and 6 months. DASH, HAP, MAM-36, and SF-36 scores were missing from one patient due to young age (< 18 years old). For the 2MWT and grip strength, missing data were not collected
Half the standard deviation of baseline scores for individuals who also had scores at 6 months
Established MCID value